Literature DB >> 18625890

Generation of functional murine cardiac myocytes from induced pluripotent stem cells.

Christina Mauritz1, Kristin Schwanke, Michael Reppel, Stefan Neef, Katherina Katsirntaki, Lars S Maier, Filomain Nguemo, Sandra Menke, Moritz Haustein, Juergen Hescheler, Gerd Hasenfuss, Ulrich Martin.   

Abstract

BACKGROUND: The recent breakthrough in the generation of induced pluripotent stem (iPS) cells, which are almost indistinguishable from embryonic stem (ES) cells, facilitates the generation of murine disease- and human patient-specific stem cell lines. The aim of this study was to characterize the cardiac differentiation potential of a murine iPS cell clone in comparison to a well-established murine ES cell line. METHODS AND
RESULTS: With the use of a standard embryoid body-based differentiation protocol for ES cells, iPS cells as well as ES cells were differentiated for 24 days. Although the analyzed iPS cell clone showed a delayed and less efficient formation of beating embryoid bodies compared with the ES cell line, the differentiation resulted in an average of 55% of spontaneously contracting iPS cell embryoid bodies. Analyses on molecular, structural, and functional levels demonstrated that iPS cell-derived cardiomyocytes show typical features of ES cell-derived cardiomyocytes. Reverse transcription polymerase chain reaction analyses demonstrated expression of marker genes typical for mesoderm, cardiac mesoderm, and cardiomyocytes including Brachyury, mesoderm posterior factor 1 (Mesp1), friend of GATA2 (FOG-2), GATA-binding protein 4 (GATA4), NK2 transcription factor related, locus 5 (Nkx2.5), T-box 5 (Tbx5), T-box 20 (Tbx20), atrial natriuretic factor (ANF), myosin light chain 2 atrial transcripts (MLC2a), myosin light chain 2 ventricular transcripts (MLC2v), alpha-myosin heavy chain (alpha-MHC), and cardiac troponin T in differentiation cultures of iPS cells. Immunocytology confirmed expression of cardiomyocyte-typical proteins including sarcomeric alpha-actinin, titin, cardiac troponin T, MLC2v, and connexin 43. iPS cell cardiomyocytes displayed spontaneous rhythmic intracellular Ca(2+) fluctuations with amplitudes of Ca(2+) transients comparable to ES cell cardiomyocytes. Simultaneous Ca(2+) release within clusters of iPS cell-derived cardiomyocytes indicated functional coupling of the cells. Electrophysiological studies with multielectrode arrays demonstrated functionality and presence of the beta-adrenergic and muscarinic signaling cascade in these cells.
CONCLUSIONS: iPS cells differentiate into functional cardiomyocytes. In contrast to ES cells, iPS cells allow derivation of autologous functional cardiomyocytes for cellular cardiomyoplasty and myocardial tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625890     DOI: 10.1161/CIRCULATIONAHA.108.778795

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  173 in total

Review 1.  Vascular potential of human pluripotent stem cells.

Authors:  Ionela Iacobas; Archana Vats; Karen K Hirschi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-07       Impact factor: 8.311

2.  Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells.

Authors:  Nan Cao; Zumei Liu; Zhongyan Chen; Jia Wang; Taotao Chen; Xiaoyang Zhao; Yu Ma; Lianju Qin; Jiuhong Kang; Bin Wei; Liu Wang; Ying Jin; Huang-Tian Yang
Journal:  Cell Res       Date:  2011-12-06       Impact factor: 25.617

Review 3.  Dynamics of proteins in Golgi membranes: comparisons between mammalian and plant cells highlighted by photobleaching techniques.

Authors:  T H Ward; F Brandizzi
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

4.  Recent concepts for the roles of progenitor/stem cell niche in heart repair.

Authors:  Yuliang Feng; Xi-Yong Yu; Yigang Wang
Journal:  Am J Cardiovasc Dis       Date:  2011-12-15

5.  Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors.

Authors:  Ruth Olmer; Andreas Lange; Sebastian Selzer; Cornelia Kasper; Axel Haverich; Ulrich Martin; Robert Zweigerdt
Journal:  Tissue Eng Part C Methods       Date:  2012-06-04       Impact factor: 3.056

6.  Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature.

Authors:  Huansheng Xu; B Alexander Yi; Hao Wu; Christoph Bock; Hongcang Gu; Kathy O Lui; Joo-Hye C Park; Ying Shao; Alyssa K Riley; Ibrahim J Domian; Erding Hu; Robert Willette; John Lepore; Alexander Meissner; Zhong Wang; Kenneth R Chien
Journal:  Cell Res       Date:  2011-11-08       Impact factor: 25.617

Review 7.  Stem cell therapy for ischemic heart disease.

Authors:  Mohammad Nurulqadr Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

8.  A novel miniaturized multimodal bioreactor for continuous in situ assessment of bioartificial cardiac tissue during stimulation and maturation.

Authors:  George Kensah; Ina Gruh; Jörg Viering; Henning Schumann; Julia Dahlmann; Heiko Meyer; David Skvorc; Antonia Bär; Payam Akhyari; Alexander Heisterkamp; Axel Haverich; Ulrich Martin
Journal:  Tissue Eng Part C Methods       Date:  2011-01-14       Impact factor: 3.056

9.  [Diminishing borders between cardiology and cardiothoracic surgery: quo vadis?].

Authors:  T Schilling; R Bekeredjian; A Haverich; H A Katus
Journal:  Chirurg       Date:  2010-12       Impact factor: 0.955

10.  Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating.

Authors:  Adam J Engler; Christine Carag-Krieger; Colin P Johnson; Matthew Raab; Hsin-Yao Tang; David W Speicher; Joseph W Sanger; Jean M Sanger; Dennis E Discher
Journal:  J Cell Sci       Date:  2008-10-28       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.